1887
Research Open Access
Like 0

Abstract

Background

A point prevalence survey (PPS) on healthcare-associated infections (HAI) and antimicrobial use was conducted in Swiss acute care hospitals in 2017.

Aim

Our objective was to assess antimicrobial use in Swiss acute care hospitals.

Methods

All patients hospitalised in any acute care hospital in Switzerland were eligible. We used the most recent version of the PPS protocol of the European Centre for Disease Prevention and Control.

Results

Data from 12,931 patients of 96 hospitals were collected. Of these, 4,265 (33%; 95% confidence interval (CI): 32.2–33.8) were on 5,354 antimicrobials for 4,487 indications. Most of the 2,808 therapeutic indications addressed 1,886 community-acquired infections (67.2%; 95% CI: 65.4–68.9). Of the 1,176 surgical prophylaxes, 350 (29.8%; 95% CI: 27.1–32.4) exceeded the duration of 1 day. Of the 1,090 antimicrobial regimens that were changed, 309 (28.3%; 95% CI: 25.7–31.0) were escalated and 337 (30.9%; 95% CI: 28.2–33.7) were de-escalated. Amoxicillin/clavulanic acid was the most frequent antimicrobial (18.8%; 95% CI: 17.7–19.8), prescribed mainly for therapeutic indications (76.0%; 95% CI: 73.3–78.7). A total of 1,931 (37.4%; 95% CI: 36.1–38.8) of the 5,158 antimicrobials for systemic use were broad-spectrum antibiotics, most frequently third- and fourth-generation cephalosporins (35.9%; 95% CI: 33.8–38.1).

Conclusions

Antimicrobial consumption was at European average, the use of broad-spectrum antibiotics in the lower third. Swiss acute care hospitals should invest in antimicrobial stewardship, particularly in reducing the use of broad-spectrum antibiotics.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.33.1900015
2019-08-15
2019-08-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.33.1900015
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/33/eurosurv-24-33-3.html?itemId=/content/10.2807/1560-7917.ES.2019.24.33.1900015&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011-2012. Stockholm: ECDC; 2013. Available from: https://ecdc.europa.eu/en/publications-data/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-0
  2. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018;18(3):e99-106.  https://doi.org/10.1016/S1473-3099(17)30485-1  PMID: 29102325 
  3. Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J. Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations. Infection. 2009;37(5):432-7.  https://doi.org/10.1007/s15010-009-8325-y  PMID: 19499184 
  4. Vernaz N, Huttner B, Muscionico D, Salomon JL, Bonnabry P, López-Lozano JM, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother. 2011;66(4):928-35.  https://doi.org/10.1093/jac/dkq525  PMID: 21393172 
  5. Karp J, Edman-Wallér J, Toepfer M, Lundqvist A, Jacobsson G. Clostridioides difficile incidence related to in-hospital cephalosporin use: a tale of two highly comparable hospitals. J Antimicrob Chemother. 2019;74(1):182-9.  https://doi.org/10.1093/jac/dky408  PMID: 30358837 
  6. Wilcox MH, Chalmers JD, Nord CE, Freeman J, Bouza E. Role of cephalosporins in the era of Clostridium difficile infection. J Antimicrob Chemother. 2017;72(1):1-18.  https://doi.org/10.1093/jac/dkw385  PMID: 27659735 
  7. Carignan A, Allard C, Pépin J, Cossette B, Nault V, Valiquette L. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis. 2008;46(12):1838-43.  https://doi.org/10.1086/588291  PMID: 18462108 
  8. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118(2):717-22.  https://doi.org/10.1542/peds.2005-2677  PMID: 16882828 
  9. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66(2):398-407.  https://doi.org/10.1093/jac/dkq412  PMID: 21106563 
  10. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2011;55(4):1598-605.  https://doi.org/10.1128/AAC.01157-10  PMID: 21220533 
  11. Stewardson AJ, Allignol A, Beyersmann J, Graves N, Schumacher M, Meyer R, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Euro Surveill. 2016;21(33):30319.  https://doi.org/10.2807/1560-7917.ES.2016.21.33.30319  PMID: 27562950 
  12. Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990-1001.  https://doi.org/10.1016/S1473-3099(17)30325-0  PMID: 28629876 
  13. Goossens H, Ferech M, Vander Stichele R, Elseviers MESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-87.  https://doi.org/10.1016/S0140-6736(05)70799-6  PMID: 15708101 
  14. Ansari F, Erntell M, Goossens H, Davey P. The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006. Clin Infect Dis. 2009;49(10):1496-504.  https://doi.org/10.1086/644617  PMID: 19842976 
  15. European Surveillance of Antimicrobial Consumption Network (ESAC-Net). Summary of the latest data on antibiotic consumption in the European Union. ESAC-Net surveillance data. Stockholm: European Centre for Disease Prevention and Control; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20FINALwith%20erratum.pdf
  16. Plachouras D, Kärki T, Hansen S, Hopkins S, Lyytikäinen O, Moro ML, et al. Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. Euro Surveill. 2018;23(46).  https://doi.org/10.2807/1560-7917.ES.23.46.1800393  PMID: 30458917 
  17. Zingg W, Hopkins S, Gayet-Ageron A, Holmes A, Sharland M, Suetens C, et al. Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infect Dis. 2017;17(4):381-9.  https://doi.org/10.1016/S1473-3099(16)30517-5  PMID: 28089444 
  18. European Centre for Disease Prevention and Control (ECDC). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals: protocol version 5.3. Stockholm: ECDC; 2016. Available from: https://ecdc.europa.eu/en/publications-data/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-3
  19. Suetens C, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML, et al. The Healthcare-Associated Infections Prevalence Study Group. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23(46).  https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516  PMID: 30458912 
  20. Swiss Federal Office of Public Health (FOPH). Gesundheit 2020 - Health 2020 - a comprehensive health care strategy. Liebefeld: FOPH; 2013. Available from: https://www.bag.admin.ch/bag/en/home/strategie-und-politik/gesundheit-2020/eine-umfassende-strategie-fuer-das-gesundheitswesen.html
  21. Swiss Federal Office of Public Health (FOPH). National strategy for the monitoring, prevention and control of healthcare-associated infections (NOSO Strategy). Liebefeld: FOPH 2016. Available from: https://www.bag.admin.ch/bag/en/home/das-bag/publikationen/broschueren/publikationen-uebertragbare-krankheiten/publikation-nationale-strategie-noso.html
  22. Swiss Federal Office of Public Health (FOPH). Strategy on antibiotic resistance (StAR). Liebefeld: FOPH; 2015. Available from: https://www.bag.admin.ch/bag/en/home/das-bag/publikationen/broschueren/publikationen-uebertragbare-krankheiten/strategie-anbitiotikaresistenzen-schweiz.html
  23. Metsini A, Vazquez M, Sommerstein R, Marschall J, Voide C, Troillet N, et al. Point prevalence of healthcare-associated infections and antibiotic use in three large Swiss acute-care hospitals. Swiss Med Wkly. 2018;148:w14617. PMID: 29698542 
  24. Behnke M, Aghdassi SJ, Hansen S, Diaz LAP, Gastmeier P, Piening B. The prevalence of nosocomial infection and antibiotic use in German hospitals. Dtsch Arztebl Int. 2017;114(50):851-7.  https://doi.org/10.3238/arztebl.2017.0851  PMID: 29271343 
  25. Zarb P, Ansari F, Muller A, Vankerckhoven V, Davey PG, Goossens H. Drug utilization 75% (DU75%) in 17 European hospitals (2000-2005): results from the ESAC-2 Hospital Care Sub Project. Curr Clin Pharmacol. 2011;6(1):62-70.  https://doi.org/10.2174/157488411794941322  PMID: 21235461 
  26. World Health Organization (WHO). ATC/DDD Index 2019. Geneva: WHO. [Accessed: 1 Apr 2019]. Available from: https://www.whocc.no/atc_ddd_index/
  27. European Centre for Disease Prevention and Control (ECDC), European Food Safety Agency (EFSA), European Medicines Agency (EMA). ECDC, EFSA and EMA Joint Scientific Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals. EFSA J. 2017;15(10):5017.
  28. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med. 1962;110(6):847-53.  https://doi.org/10.1001/archinte.1962.03620240029006 
  29. National Healthcare Safety Network (NHSN). Surgical site infection (SSI) event. Atlanta: Centers for Disease Control and Prevention. [Accessed 12 Feb 2019]. Available from: https://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf
  30. Zingg W, Metsini A, Balmelli C, Neofytos D, Behnke M, Gardiol C, et al. Findings of the first national point prevalence survey on healthcare-associated infections in acute care hospitals in Switzerland. Euro Surveill.2019;24(33):1800603.
  31. Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998;17(1):20-4.  https://doi.org/10.1007/BF01584358  PMID: 9512177 
  32. Anresis. Hospital care. Bern: Institut für Infektionskrankheiten. [Accessed: 1 Apr 2019]. Available from: http://www.anresis.ch/index.php/hospital-care.html
  33. Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16(12):e276-87.  https://doi.org/10.1016/S1473-3099(16)30398-X  PMID: 27816413 
  34. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16(12):e288-303.  https://doi.org/10.1016/S1473-3099(16)30402-9  PMID: 27816414 
/content/10.2807/1560-7917.ES.2019.24.33.1900015
Loading

Data & Media loading...

Supplementary data

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error